Yinlu Ding
Papers
1
Total Citations
4
H-Index
1
About
Yinlu Ding is a leading surgical oncologist whose research focuses on optimizing perioperative care for gastric cancer patients, particularly those undergoing advanced minimally invasive procedures. Her major contributions center on the intersection of neoadjuvant chemotherapy and surgical outcomes, with a specific emphasis on the role of the gut microbiome in recovery. In her landmark study protocol, "Effect of perioperative probiotic supplements on the short-term clinical outcomes of patients undergoing laparoscopic or robotic radical gastrectomy after neoadjuvant chemotherapy," Ding proposes a novel intervention to mitigate the adverse effects of chemotherapy and surgery. This multicenter randomized controlled trial, which has already garnered 4 citations since its 2025 publication, addresses a critical gap in managing advanced gastric cancer patients who require neoadjuvant therapy. By investigating whether probiotic supplementation can improve short-term clinical outcomes, Ding’s work has the potential to transform standard perioperative protocols. Her research is particularly notable for its rigorous methodology and focus on personalized, microbiome-based therapies. As a key member of the GISSG2023 study group, Ding continues to push boundaries in gastric cancer treatment, making her a rising authority in surgical oncology and perioperative medicine.
Research Focus
Key Achievements
Top Papers
- 1